Brought to you by 
Xcel licenses exclusive rights to Viatris's epilepsy compound
05 Apr 2011
Executive Summary
Viatris GMBH licensed Xcel Pharmaceuticals (develops therapeutics to treat CNS disorders) exclusive worldwide rights to its Phase IIb retigabine for epilepsy.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Xcel licenses exclusive rights to Viatris's epilepsy compound
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice